Revvity Raises Full-Year Profit Forecast on Strong Diagnostics Demand

Medical equipment maker Revvity, Inc. raised its full-year 2025 profit outlook after reporting solid demand in its diagnostics business.

During the third quarter, the company’s diagnostics unit generated $356.1 million in revenue, exceeding analyst expectations of $350.6 million. Overall quarterly revenue reached $699 million, just below the estimated $700.5 million.

Adjusted earnings per share came in at $1.18, beating forecasts of $1.14. In response, Revvity increased its full-year adjusted EPS guidance to a range of $4.90 to $5.00, up from the prior outlook of $4.85 to $4.95.

Despite the raised guidance, shares fell around 2.7% in pre-market trading. Investors focused on the small revenue miss.

Revvity’s diagnostics strength comes amid a broader resurgence in life-science and diagnostic services, as pharmaceutical companies expand drug development and testing workflows.

Looking ahead, analysts will watch whether Revvity can sustain growth in diagnostics while navigating headwinds in biotech spending and global manufacturing shifts.